Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

5.6%

1 terminated out of 18 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

55%

6 of 11 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (5)
Early P 1 (1)
P 1 (8)
P 2 (1)
P 3 (1)

Trial Status

Completed11
Active Not Recruiting3
Not Yet Recruiting1
Terminated1
Recruiting1
Withdrawn1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT01503086Not ApplicableCompleted

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

NCT02359565Phase 1Active Not Recruiting

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

NCT06630338Not Yet Recruiting

Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements

NCT02389309Phase 1Active Not Recruiting

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

NCT02698254Not ApplicableActive Not RecruitingPrimary

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

NCT02754544Not ApplicableRecruiting

Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

NCT04588246Phase 3Terminated

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT02020720Early Phase 1Completed

18F-DOPA-PET in Planning Surgery in Patients With Gliomas

NCT02323880Phase 1Completed

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT03071913Completed

Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

NCT02658981Phase 1Completed

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

NCT02661282Phase 1Completed

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT01609790Phase 2Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

NCT01904123Phase 1Completed

STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain

NCT02167204Not ApplicableCompleted

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

NCT02575027Not ApplicableCompleted

Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01250470Phase 1Completed

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT02521090Phase 1Withdrawn

EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Showing all 18 trials

Research Network

Activity Timeline